The ruling class of the United States is in the process of releasing a vaccine for the monkeypox. With a whopping 4 possible cases and 2 confirmed cases in the entire country, the only thing on the ruler’s mind is getting more shots in more people.
“I can report that there has been a request for release of the Jynneos vaccine from the National Stockpile for some of the high-risk contacts of some of the early patients, so that is actively happening right now,” Dr. Jennifer McQuiston, deputy director of the Division of High Consequence Pathogens and Pathology within the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, said Monday.
McQuiston said the United States has a “good stock” of vaccines because it has been preparing for the possibility of needing to use doses for smallpox. The two-dose Jynneos vaccine is licensed to prevent smallpox and specifically to prevent monkeypox. in the U.S. “Right now, we have over 1,000 doses of that available, and we expect that level to ramp up very quickly in the coming weeks as the company provides more doses to us,” McQuiston said, according to CNN.
There is another smallpox vaccine licensed in the United States, ACAM2000, that could be used to prevent monkeypox, she said, and the country has more than 100 million doses.
“ACAM2000 is an older-generation smallpox vaccine that has some potential significant side effects with it. So a decision to use that widely would have to have some serious discussion behind it,” McQuiston said.
Overall, “we are hoping to maximize vaccine distribution to those that we know would benefit from it,” she said. “Those are people who’ve had contact with a known monkeypox patients, health care workers, very close personal contact, and those in particular who might be at high risk for severe disease.” –CNN
“It is likely that there are going to be additional cases reported in the United States,” she said.